ANNOUNCEMENT OF RESULTS OF PUBLIC OFFER

Dr. Max Funding CR, s.r.o.
Bonds with a fixed interest rate of 6.75% p.a.
in an expected aggregate nominal amount of up to CZK 1,250,000,000 due in 2029
ISIN CZ0003566234
(the "Bonds")

Prague, 20 November 2024

Issuer of the Bonds, the company Dr. Max Funding CR, s.r.o. (the "Issuer"), in accordance with the Prospectus approved by CNB decision ref. no. 2024/115394/CNB/650, file no. S-Sp- 2024/00246/CNB/653 dated 9 October 2024, which became final and effective on 11 October 2024, hereby announces that:

Based on strong investor demand, the aggregate nominal amount of the issued Bonds is CZK 1,250,000,000. The Bonds are listed and traded on the Regulated Market of the Prague Stock Exchange.

Capitalized terms not defined in this announcement have the meaning assigned to them in the Prospectus of the Bonds, which is accessible on the website of the Issuer at www.drmaxfundingcr.cz, in the section Bonds. This announcement is published in the same manner as the Prospectus and it must be read together with the Prospectus (and its amendments, if any).

About the Dr. Max Group

Dr.Max is the number one pharmacy chain in Central Eastern Europe. In 2023, Dr.Max was operating within 3 business segments (pharmacy retail, pharmaceutical wholesale, and pharma marketing and sales), in 17 European countries, with ~3000 pharmacies and generated revenues of EUR 4.23 billion and EBITDA of EUR 323 million. Dr.Max is dedicated to improving the level of healthcare available by guaranteeing access to a broad, high-quality assortment of medicines and pharmacy services at affordable prices. Dr.Max is owned by the Penta Group.